Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gynecological Oncology

This article is part of the Research TopicAdvances in Diagnosis and Treatment of Endometrial CancerView all 22 articles

Vaginal lavage fluid can serve as a reliable method for early screening of endometrial cancer: a proof-of-concept study

Provisionally accepted
Yibing  LiYibing LiPing  RenPing Ren*Jiazhen  HuangJiazhen HuangShuang  TanShuang TanNing  WangNing Wang*
  • The Second Hospital of Dalian Medical University, Dalian, China

The final, formatted version of the article will be published soon.

Background: Endometrial cancer (EC) is one of the malignant tumors in the female reproductive system, and effective screening is urgently needed to reduce mortality. At present, the main screening method for endometrial cancer is ultrasound combined with curettage and pathological examination. We plan to explore a non-invasive, convenient, and low-cost new screening method for EC, providing a more convenient way for early screening of EC. Methods: We included a total of 11 patients with stage IA EC, and collected 8-10ml of blood, pathological paraffin sections, and vaginal lavage fluid for each patient. The collection of vaginal lavage fluid was performed before the patient's curettage or hysteroscopy for pathological examination. And perform high-throughput sequencing and further analysis on it. Results: In 11 cases with matched tumor and blood tissues, the extracted ctDNA concentration was significantly higher in vaginal lavage fluid than in plasma. The average and median MAF of different samples from paired tissue patients were significantly higher in vaginal lavage supernatant and sediment than in plasma. The types of genomic changes in the supernatant of vaginal lavage fluid are relatively consistent with those in the sediment and tumor tissue samples, but significantly different from those in the plasma. In addition, among the six most frequently mutated genes in this study, the consistency between vaginal lavage fluid supernatant and vaginal lavage fluid precipitation and tumor tissue genomic changes was significantly higher than in plasma. According to the results of 11 cases that provided tumor tissue samples, the genomic changes detected between the supernatant or precipitate of vaginal lavage fluid and tumor tissue were significantly consistent compared to those detected between tumor tissue and plasma. The potential targets for targeted treatment of endometrial cancer (KRAS, PIK3CA, MLH1, MSH6, POLE, PTEN) showed more significant changes in the supernatant of vaginal lavage fluid. Conclusion: The supernatant/precipitate of vaginal lavage fluid has significant clinical significance for early screening of endometrial cancer, and may also have potential clinical value in guiding targeted therapy and evaluating prognosis. Vaginal lavage fluid gene sequencing may serve as a new method for initial screening of endometrial cancer.

Keywords: CtDNA, Early Screening, endometrial cancer, high-throughput sequencing, vaginal lavage fluid

Received: 31 Oct 2025; Accepted: 04 Dec 2025.

Copyright: © 2025 Li, Ren, Huang, Tan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Ping Ren
Ning Wang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.